242 related articles for article (PubMed ID: 19468291)
1. Molecular targets for treatment of inflammatory breast cancer.
Yamauchi H; Cristofanilli M; Nakamura S; Hortobagyi GN; Ueno NT
Nat Rev Clin Oncol; 2009 Jul; 6(7):387-94. PubMed ID: 19468291
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy in inflammatory breast cancer.
Yamauchi H; Ueno NT
Cancer; 2010 Jun; 116(11 Suppl):2758-9. PubMed ID: 20503407
[TBL] [Abstract][Full Text] [Related]
3. Novel targeted therapies in inflammatory breast cancer.
Cristofanilli M
Cancer; 2010 Jun; 116(11 Suppl):2837-9. PubMed ID: 20503416
[TBL] [Abstract][Full Text] [Related]
4. [Systemic treatments of inflammatory breast cancer: an overview].
Monneur A; Bertucci F; Viens P; Gonçalves A
Bull Cancer; 2014 Dec; 101(12):1080-8. PubMed ID: 25475708
[TBL] [Abstract][Full Text] [Related]
5. Integrating biological agents into systemic therapy of breast cancer: trastuzumab, lapatinib, bevacizumab.
Eniu A
J BUON; 2007 Sep; 12 Suppl 1():S119-26. PubMed ID: 17935269
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis, lymphangiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer: a review of the current knowledge.
Vermeulen PB; van Golen KL; Dirix LY
Cancer; 2010 Jun; 116(11 Suppl):2748-54. PubMed ID: 20503405
[TBL] [Abstract][Full Text] [Related]
7. Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study.
Van der Auwera I; Van den Eynden GG; Colpaert CG; Van Laere SJ; van Dam P; Van Marck EA; Dirix LY; Vermeulen PB
Clin Cancer Res; 2005 Nov; 11(21):7637-42. PubMed ID: 16278382
[TBL] [Abstract][Full Text] [Related]
8. Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.
Jhaveri K; Teplinsky E; Silvera D; Valeta-Magara A; Arju R; Giashuddin S; Sarfraz Y; Alexander M; Darvishian F; Levine PH; Hashmi S; Zolfaghari L; Hoffman HJ; Singh B; Goldberg JD; Hochman T; Formenti S; Esteva FJ; Moran MS; Schneider RJ
Clin Breast Cancer; 2016 Apr; 16(2):113-22.e1. PubMed ID: 26774497
[TBL] [Abstract][Full Text] [Related]
9. What is the best treatment recommendation for HER2+ IBC with residual disease?-a narrative review.
Zakon DB; Valero V
Chin Clin Oncol; 2021 Dec; 10(6):59. PubMed ID: 35016513
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
Johnston S; Trudeau M; Kaufman B; Boussen H; Blackwell K; LoRusso P; Lombardi DP; Ben Ahmed S; Citrin DL; DeSilvio ML; Harris J; Westlund RE; Salazar V; Zaks TZ; Spector NL
J Clin Oncol; 2008 Mar; 26(7):1066-72. PubMed ID: 18212337
[TBL] [Abstract][Full Text] [Related]
11. HER-2-positive metastatic breast cancer: trastuzumab and beyond.
Metro G; Mottolese M; Fabi A
Expert Opin Pharmacother; 2008 Oct; 9(15):2583-601. PubMed ID: 18803447
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer.
Matsuda N; Wang X; Lim B; Krishnamurthy S; Alvarez RH; Willey JS; Parker CA; Song J; Shen Y; Hu J; Wu W; Li N; Babiera GV; Murray JL; Arun BK; Brewster AM; Reuben JM; Stauder MC; Barnett CM; Woodward WA; Le-Petross HTC; Lucci A; DeSnyder SM; Tripathy D; Valero V; Ueno NT
JAMA Oncol; 2018 Sep; 4(9):1207-1213. PubMed ID: 29879283
[TBL] [Abstract][Full Text] [Related]
13. Gain in cellular organization of inflammatory breast cancer: A 3D in vitro model that mimics the in vivo metastasis.
Morales J; Alpaugh ML
BMC Cancer; 2009 Dec; 9():462. PubMed ID: 20028562
[TBL] [Abstract][Full Text] [Related]
14. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT
BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory breast cancer: novel preoperative therapies.
Overmoyer BA
Clin Breast Cancer; 2010 Feb; 10(1):27-32. PubMed ID: 20133255
[TBL] [Abstract][Full Text] [Related]
16. The role of inflammation in inflammatory breast cancer.
Fouad TM; Kogawa T; Reuben JM; Ueno NT
Adv Exp Med Biol; 2014; 816():53-73. PubMed ID: 24818719
[TBL] [Abstract][Full Text] [Related]
17. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
18. Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer.
Damasceno M
Curr Opin Oncol; 2011 Apr; 23 Suppl():S3-9. PubMed ID: 21490481
[TBL] [Abstract][Full Text] [Related]
19. Primary systemic chemotherapy for inflammatory breast cancer.
Sinclair S; Swain SM
Cancer; 2010 Jun; 116(11 Suppl):2821-8. PubMed ID: 20503414
[TBL] [Abstract][Full Text] [Related]
20. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
